AU2023269343A1 - Treatment or prevention of dengue viral infection - Google Patents

Treatment or prevention of dengue viral infection Download PDF

Info

Publication number
AU2023269343A1
AU2023269343A1 AU2023269343A AU2023269343A AU2023269343A1 AU 2023269343 A1 AU2023269343 A1 AU 2023269343A1 AU 2023269343 A AU2023269343 A AU 2023269343A AU 2023269343 A AU2023269343 A AU 2023269343A AU 2023269343 A1 AU2023269343 A1 AU 2023269343A1
Authority
AU
Australia
Prior art keywords
days
compound
kcal
fat
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023269343A
Other languages
English (en)
Inventor
Oliver ACKAERT
Tristan BAGUET
Claire BALMAIN
Nele GOEYVAERTS
Guillermo HERRERA-TARACENA
Dymphy HUNTJENS
Freya RASSCHAERT
Bram SCHROYEN
Ivan SOMERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AU2023269343A1 publication Critical patent/AU2023269343A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023269343A 2022-05-12 2023-05-01 Treatment or prevention of dengue viral infection Pending AU2023269343A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341074P 2022-05-12 2022-05-12
US63/341,074 2022-05-12
PCT/IB2023/054527 WO2023218285A1 (en) 2022-05-12 2023-05-01 Treatment or prevention of dengue viral infection

Publications (1)

Publication Number Publication Date
AU2023269343A1 true AU2023269343A1 (en) 2025-01-02

Family

ID=86558745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023269343A Pending AU2023269343A1 (en) 2022-05-12 2023-05-01 Treatment or prevention of dengue viral infection

Country Status (8)

Country Link
US (1) US20250281457A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522163A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517683A (cg-RX-API-DMAC7.html)
CN (1) CN119173261A (cg-RX-API-DMAC7.html)
AU (1) AU2023269343A1 (cg-RX-API-DMAC7.html)
CA (1) CA3257185A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400144A (cg-RX-API-DMAC7.html)
WO (1) WO2023218285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12022551160A1 (en) * 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease

Also Published As

Publication number Publication date
JP2025517683A (ja) 2025-06-10
WO2023218285A1 (en) 2023-11-16
US20250281457A1 (en) 2025-09-11
TW202400144A (zh) 2024-01-01
EP4522163A1 (en) 2025-03-19
CA3257185A1 (en) 2023-11-16
CN119173261A (zh) 2024-12-20

Similar Documents

Publication Publication Date Title
US7741374B1 (en) Methods of use of fenofibric acid
US20030147950A1 (en) Modified release tamsulosin tablets
CA2740146C (en) Immediate release dosage forms of sodium oxybate
US9468610B2 (en) 1-aminocyclohexane derivatives for the treatment of hearing loss
CA2461693A1 (en) Dosage form for treatment of diabetes mellitus
TW201238612A (en) Therapeutic compositions
US20200222425A1 (en) Composition and method for oral delivery of androgen prodrugs
KR20210119906A (ko) 포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법
EP4240331B1 (en) Solid formulation
EP4103158A1 (en) Composition comprising ramipril and indapamide
KR20040007665A (ko) 파라세타몰을 포함하는 연하 정제
US20250281457A1 (en) Treatment or prevention of dengue viral infection
KR102548747B1 (ko) 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제
WO2020089760A1 (en) Fixed dose pharmaceutical composition comprising combination of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
HK40120143A (en) Treatment or prevention of dengue viral infection
JP2023071921A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
JP4866170B2 (ja) 睡眠薬の放出制御医薬組成物及びその製造方法
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
WO2012148225A2 (en) Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
HK40099185A (en) Solid formulation
RU2020143156A (ru) Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и бигуанидное гипогликемическое лекарственное средство, а также способ их приготовления и их применение
HK1235695A1 (en) Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
JPH047323B2 (cg-RX-API-DMAC7.html)
KR20150057263A (ko) 레베티라세탐 또는 이의 약제학적으로 허용되는 염을 함유하는 서방성 제제 및 이의 제조방법